Oral or intravenous trimethoprim-sulfamethoxazole therapy for shigellosis.

Abstract

A review of the literature concerning shigellosis treated with trimethoprim-sulfamethoxazole (TMP-SMZ) revealed comparative studies of 149 cases and noncomparative studies of 147 cases. Bacteriologic and clinical success rates were greater than or equal to 90% and TMP-SMZ compared favorably with alternative drug therapy. In the present study TMP-SMZ was given intravenously as initial therapy to 11 children hospitalized for severe shigella colitis. Bacteriologic and clinical responses were comparable to those observed with oral TMP-SMZ therapy. Pharmacokinetic studies revealed substantial differences between the responses of these children and those reported for adult patients; a higher ratio of SMZ to TMP (50:1) was found in children. It is concluded that TMP-SMZ is effective therapy for shigellosis and is the drug of choice in areas where ampicillin resistance is prevalent.

• Authors: J D Nelson, H Kusmiesz, S Shelton
• Journal: Reviews of infectious diseases (Rev Infect Dis) 1982 Mar-Apr Vol. 4 Issue 2 Pg. 546-50 ISSN: 0162-0886 [Print] United States
• PMID: 6981170 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Drug Combinations
• Trimethoprim, Sulfamethoxazole Drug Combination
• Trimethoprim
• Sulfamethoxazole

Topics

• Administration, Oral
• Carrier State (drug therapy)
• Child, Preschool
• Drug Combinations (administration & dosage, metabolism)
• Dysentery, Bacillary (drug therapy, microbiology)
• Female
• Humans
• Infant
• Infusions, Parenteral
• Kinetics
• Male
• Sulfamethoxazole (administration & dosage, metabolism)
• Trimethoprim (administration & dosage, metabolism)
• Trimethoprim, Sulfamethoxazole Drug Combination